Severe Hypertriglyceridemia: A 10-Year Review in a Portuguese Hospital.
cardiovascular risk (cvr)
fibrates
hypertriglyceridemia-induced acute pancreatitis
severe hypertriglyceridemia
therapeutic plasmapheresis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
30
06
2023
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Severe hypertriglyceridemia (SHTG) is a rare condition associated with serious complications, such as acute pancreatitis (AP), and the best treatment is still a matter of discussion. The aim of this study is to outline the demographics, management, and outcomes (recurrence and mortality) of complications in patients with SHTG. A retrospective, observational, and analytical study was carried out by obtaining clinical data from the electronic health records of patients with SHTG admitted to the Internal and Intensive Medicine units from the 1 The cohort included 17 patients. The most common complication was AP (13/17 = 76.5%). Admission to the intensive care unit (ICU) was observed in 84.2%. Among patients with AP, the most commonly administered therapies were insulin (82.4%) and fibrates (76.5%). Plasmapheresis was used in 58.8%, and the criteria for using this technique were mainly based on clinical and laboratory abnormalities. There were no deaths. The readmission rate at 30 days was 36.3%. This study shows the morbidity profile associated with SHTG, with a high level of ICU admissions and also a high level of the use of plasmapheresis. In our population, this approach had good results, and this should be highlighted as there are no clear international guidelines for this intervention. Distinguishing between patients with familial chylomicronemia syndrome or with multifactorial chylomicronemia is important as recent specific therapy for lipoprotein lipase (LPL) genetic deficit is available. In the near future, the performance of a genetic study should be considered in patients with SHTG as an attempt to avoid the high recurrence rate of complications of this disease.
Identifiants
pubmed: 37529514
doi: 10.7759/cureus.41239
pmc: PMC10387820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e41239Informations de copyright
Copyright © 2023, Laranjeira et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Heart J. 2020 Jun 21;41(24):2313-2330
pubmed: 32052833
PLoS One. 2014 Jul 21;9(7):e102748
pubmed: 25047332
Biomed Res Int. 2018 Jul 26;2018:4721357
pubmed: 30148167
Science. 1947 Aug 29;106(2748):190-1
pubmed: 17749166
World J Gastroenterol. 2008 Jul 28;14(28):4558-61
pubmed: 18680239
Eur Heart J. 2020 Jan 1;41(1):99-109c
pubmed: 31764986
J Clin Gastroenterol. 2014 Mar;48(3):195-203
pubmed: 24172179
J Clin Apher. 2019 Jun;34(3):171-354
pubmed: 31180581
Lipids Health Dis. 2021 Jul 18;20(1):72
pubmed: 34275452
Acta Gastroenterol Belg. 2017 Jan-Mar;80(1):71-74
pubmed: 29364102
Circulation. 2019 Sep 17;140(12):e673-e691
pubmed: 31422671
J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89
pubmed: 22962670
Biochim Biophys Acta. 2012 May;1821(5):867-75
pubmed: 22015388
Drugs. 2015 Feb;75(2):175-82
pubmed: 25559420
BMJ. 2020 Oct 12;371:m3109
pubmed: 33046451
Hosp Pharm. 2017 Nov;52(10):675-678
pubmed: 29276238
Turk J Emerg Med. 2023 Jan 09;23(2):111-118
pubmed: 37169033
J Family Med Prim Care. 2022 Jun;11(6):3360-3367
pubmed: 36119312
Artif Organs. 2009 Dec;33(12):1096-102
pubmed: 20091936
Transfus Apher Sci. 2016 Feb;54(1):99-102
pubmed: 26947356
Metabolites. 2023 Apr 30;13(5):
pubmed: 37233662
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
Diabetes Obes Metab. 2020 Mar;22(3):279-289
pubmed: 31742844